UroGen Pharma Ltd (Nasdaq: URGN) has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for a potential new treatment for patients with low-grade non-muscle invasive bladder cancer (LG NMIBC), the biopharmaceutical company reported on Wednesday.
The application relates to UGN-102 (VesiGel, mitomycin gel for intravesical instillation), which has the potential to become the first front-line non-surgical therapy for patients with LG NMIBC.
The company's proposed Phase 2b single-arm, open-label, multi-centre trial is designed to assess the efficacy and safety of UGN-102 as a first-line chemoablation agent in the treatment of patients with LG NMIBC at risk for recurrence. Transurethral resection of bladder tumor (TURBT) followed by adjuvant chemotherapy or immunotherapy is the current standard of care.
NMIBC accounts for approximately 80% of all new cases of bladder cancer diagnosed in the United States each year, and the majority of patients face life-long, repetitive surgical treatment for cancer recurrence, UroGen said.
The company expects to start the Phase 2b clinical trial in the third quarter of 2018.
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data